Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound

Abstract

The invention is also directed to pharmaceutical composition comprising a compound having anti-Xa activity, a platelet aggregation antagonist compound and a pharmaceutically acceptable carrier. The invention is also directed to a method of treating or preventing a thrombogenic condition associated with a thrombosis related ischemic disorder in a patient comprising administering to said patient pharmaceutically effective amounts of a compound having anti-Xa activity and a platelet aggregation antagonist compound. In addition, this invention is directed to the use of pharmaceutically effective amounts of a compound having anti-Xa activity and a platelet aggregation antagonist compound in the preparation of a medicament for treating or preventing a physiological condition associated with thrombosis related ischemic disorder. Furthermore, this invention is directed to a kit for treating or preventing a physiological condition associated with thrombosis related ischemic disorder, said kit comprising a plurality of separate containers, wherein at least one of said containers contains a compound having anti-Xa activity and at least another of said containers contains a platelet aggregation antagonist compound, and said containers optionally contain a pharmaceutical carrier.

What is claimed is:  
     
         1 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and pharmaceutically effective amounts of a compound having anti-Xa activity and a platelet aggregation antagonist compound.  
     
     
         2 . The pharmaceutical composition according to  claim 1  wherein the compound having anti-Xa activity is a low molecular weight heparin.  
     
     
         3 . The pharmaceutical composition according to  claim 1  wherein the low molecular weight heparin is selected from the group consisting of enoxaparin, nardroparin, dalteparin, certroparin, parnaparin, reviparin, ardeparin/RD heparin/RDH or tinzaparin.  
     
     
         4 . The pharmaceutical composition according to  claim 1  wherein the low moleclular weight heparin is enoxaparin.  
     
     
         5 . The pharmaceutical composition according to  claim 1  wherein the compound having anti-Xa activity is a heparinoid compound.  
     
     
         6 . The pharmaceutical composition according to  claim 1  wherein the heparinoid compound is danaparoid.  
     
     
         7 . The pharmaceutical composition according to  claim 1  wherein the platelet aggregation antagonist compound is abciximab, N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-β-cyclohexyl alanine, N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-β-cyclohexyl alanine amide or N-(n-butylsulfonyl)-4-(piperidin-4-ylbutyloxy)-L-phenylalanine  
     
     
         8 . The pharmaceutical composition according to  claim 7  wherein the platelet aggregation antagonist compound antagonist is abciximab.  
     
     
         9 . The pharmaceutical composition according to  claim 7  wherein the platelet aggregation antagonist compound is N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-β-cyclohexyl alanine.  
     
     
         10 . The pharmaceutical composition according to  claim 7  wherein the platelet aggregation antagonist compound is N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-β-cyclohexyl alanine amide.  
     
     
         11 . The pharmaceutical composition according to  claim 7  wherein the platelet aggregation antagonist compound is N-(n-butylsulfonyl)-4-(piperidin-4-ylbutyloxy)-L-phenylalanine.  
     
     
         12 . A method of treating or preventing a physiological condition associated with a thrombosis related ischemic disorder in a patient comprising administering to said patient pharmaceutically effective amounts of a compound having anti-Xa activity and a platelet aggregation antagonist compound.  
     
     
         13 . The method of  claim 12  wherein the physiological condition is selected from stroke, atherosclerosis, anaiogenesis, thrombosis, a thromboembolic condition, disseminated intravascular coagulation, peripheral arterial occlusive disease, hemodialysis, an extra-corporeal circulation requirement associated with a surgical procedure, tissue damage caused by phospholipases A2, an acute coronary syndrome, or a thromboembolic syndrome associated with cancer, sepsis or obstetrical complications.  
     
     
         14 . The method of  claim 13  wherein the physiological condition is the acute coronary syndrome.  
     
     
         15 . The method of  claim 14  wherein the acute coronary syndrome is unstable angina or myocardial infarction.  
     
     
         16 . The method of  claim 12  wherein the treating or preventing occurs in the course of coronary artery bypass surgery or percutaneous transluminal coronary angioplasty.  
     
     
         17 . The method of  claim 12  wherein the treating or preventing occurs in the course of percutaneous transluminal coronary angioplasty. carrier.